November 12, 2010 — The US Food and Drug Administration (FDA) has approved tesamorelin acetate injection (Egrifta; Theratechnologies, Inc, and marketed by EMD Serono) as the first and only treatment ...
According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...
NEW YORK, NY, January 14, 2026 (EZ Newswire) -- Bowery Clinic today announced expanded, physician-led protocols centered on two clinically studied peptides that act upstream of growth hormone: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results